Adriana Ponton-Almodovar , Ph.D.
Biography
Adriana Ponton-Almodovar, Ph.D. earned her doctoral degree in Pharmacology and Toxicology from Michigan State University, where she focused her research on ovarian cancer chemoresistance. Specifically, how cancer cells adapt their metabolism in response to chemotherapy and the mechanism that drives cancer progression. Adriana is committed to translating her findings into the clinic, which has led her to focus on FDA drug repurposing. She is a postdoctoral scholar in Dr. Sachi Horibata's laboratory in the Precision Health Program and the Department of Pharmacology and Toxicology. Her current work focuses on investigating existing medications that could be effective in treating ovarian cancer and improving chemotherapy options for this challenging disease. Her doctoral dissertation research was supported by the NIH Integrative Pharmacological Sciences Training Program (IPSTP; T32GM142521, 2022-2024), the Aitch Foundation Fellowship (2024-2025), and the Barnett Rosenberg Endowed Research Assistantship in Biological Sciences (2025-2026). As an undergraduate at the Pontifical Catholic University of Puerto Rico, she conducted research as a Junior Research Associate of the NIH Puerto Rico IDeA Network of Biomedical Research Excellence (INBRE; P20GM103475). She also completed an NIH Postbaccalaureate Research Education Program (PREP; R25GM121220) at the University of Massachusetts Chan Medical School.
Education
Ph.D. , Department of Pharmacology and Toxicology; Precision Health Program, Michigan State University, 2026
Postbaccalaureate Trainee, Postbaccalaureate Research Education Program, University of Massachusetts Chan Medical School, 2021
Bachelor of Sciences, Biomedical Sciences, Pontifical Catholic University of Puerto Rico, 2020
Employment
Postdoctoral Scholar, Michigan State University, East Lansing, 2026 - Present
Publications
Cisplatin resistance in an ovarian cancer model is mediated by microtubule dynamics regulator TPPP3 in synergy with tubulin code rewiring. Cell reports (2026)
GPT2 mediates glutamine metabolism-driven metabolic alterations in platinum-resistant ovarian cancer cells. Scientific reports (2025)
Ovarian tumor microenvironment contributes to tumor progression and chemoresistance. Cancer Drug Resistance (2024)
The impact of poor metabolic health on aggressive breast cancer: adipose tissue and tumor metabolism Frontiers in Endocrinology (2023)
Effect of CdSTe QDs’ Crystal Size on Viability and Cytochrome P450 Activity of CHO-K1 and HEP-G2 Cells Micro (2023)